How reliable are ISPC's earnings forecasts historically?

**iSpecimen's earnings forecasts have shown significant deviations from the actual figures, indicating a lack of reliability in their historical financial projections.**

1. **Significant Variance from Estimates**: In Q2 2024, iSpecimen reported an EPS of -$19, which was above the analyst estimate of -$28. However, in Q1 2024, the company reported an EPS of -$32, below the analyst estimate of -$27. This fluctuation highlights the inconsistency between the predicted and actual earnings.
2. **Revenue Misses**: iSpecimen has also missed revenue targets. For Q2 2024, the company reported revenue of $2.86 million, which was 0.56% below the estimated $2.88 million. In Q1 2024, the revenue of $2.29 million fell short of the estimated $2.84 million by 19.37%.
3. **Year-over-Year Growth**: The net income growth rate for Q3 2024 was 31.8%, while the revenue growth rate was -4.17%. This stark contrast between net income and revenue growth further underscores the unpredictability of iSpecimen's financial performance.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|market_code|
|---|---|---|---|---|---|---|
|ISPC|ISPC.O|iSpecimen|2023 Q4|-42.287726752237944|-13.04890727570054|186|
|ISPC|ISPC.O|iSpecimen|2024 Q1|-19.339694022399758|-22.378302194734793|186|
|ISPC|ISPC.O|iSpecimen|2024 Q2|39.45873452110366|76.21121872577132|186|
|ISPC|ISPC.O|iSpecimen|2024 Q3|31.796110181369812|-4.169380192825059|186|

Given these points, it is clear that iSpecimen's earnings forecasts are not consistently reliable, and the company's actual financial performance has varied significantly from these estimates.